Pdb71 - Assessing the Relative Cost-Effectiveness of Empagliflozin and Canagliflozin for the Treatment of Type 2 Diabetes Patients With Existing Cardiovascular Disease in the Uk
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.776
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV